Cardiovascular system in Children with Cystic fibrosis

Published: 17-12-2012 Last updated: 26-04-2024

We hypothesised that cardiovascular changes already exist in children with cystic fibrosis compared with healthy control children. Therefore, we will evaluate the cardiovascular system in a group of children with cystic fibrosis compared with...

Ethical review Approved WMO

Status Recruitment stopped **Health condition type** Myocardial disorders

Study type Observational non invasive

Summary

ID

NL-OMON37600

Source

ToetsingOnline

Brief title

Triple C

Condition

- Myocardial disorders
- Congenital respiratory tract disorders

Synonym

CF or mucoviscidosis, Cystic Fibrosis

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Utrecht

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Cardiovascular, Cystic Fibrosis

Outcome measures

Primary outcome

The main study parameters are the echocardiographic measurements of the cardiovascular system (diastolic function of the right and left ventricle).

Secondary outcome

Secundary study outcome is arterial stiffness (pulse wave velocity) and the respiratory system (the lung function measurement).

Study description

Background summary

The life-expectancy of patients with cystic fibrosis is increasing and the proportion of patients with cystic fibrosis who are middle-aged is increasing. Therefore, there is a need to focus on extra-pulmonary comorbidities that affect the length and quality of life in the adult stage of the disease.1 Several studies showed that adult patients with cystic fibrosis have a decreased systolic and diastolic function of the heart (especially the right ventricle) and an increased arterial stiffness compared to healthy controls. It is unknown when these changes appear.

By our knowledge, the cardiovascular system has not been studied in children with cystic fibrosis. It is important with regard to prevention of cardiovascular disease in cystic fibrosis patients to get a better understanding of the development of this process. If cardiovascular changes already exist in early childhood, it could lead to an earlier screening for cardiovascular disease in these patients.

Study objective

We hypothesised that cardiovascular changes already exist in children with cystic fibrosis compared with healthy control children. Therefore, we will evaluate the cardiovascular system in a group of children with cystic fibrosis compared with control subjects.

Study design

Cross-sectional design

Study burden and risks

There are no risks associated with participation in this study. There is no benefit for the children in participating to this study and participation is completely voluntary.

Contacts

Public

Universitair Medisch Centrum Utrecht

Lundlaan 6 Utrecht 3508 AB NL

Scientific

Universitair Medisch Centrum Utrecht

Lundlaan 6 Utrecht 3508 AB NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Children (2-11 years)

Inclusion criteria

Children with cystic fibrosis:

- Aged 3-12 years
- Who visit the pediatric pulmonology department for their regular control visit; Health controls
- Aged 3-12 year
- Participating in the WHISTLER study

Exclusion criteria

Children with cystic fibrosis:

- Children with a history of a heart defect will be excluded from this study.;Healthy controls
- Children with a history of a heart defect will be excluded from this study.

Study design

Design

Study type: Observational non invasive

Intervention model: Other

Allocation: Non-randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Prevention

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 28-01-2013

Enrollment: 70

Type: Actual

Ethics review

Approved WMO

Date: 17-12-2012

Application type: First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL39258.041.12